Key Insights

Highlights

Treatment Research

5 treatments under study, led by Epcoritamab

Related Conditions

Often studied with 10 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
Phase 2 (3)

Trial Status

Recruiting2
Not Yet Recruiting1

Clinical Trials (3)

Showing 3 of 3 trials
NCT07819214Phase 2Not Yet Recruiting

Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI

NCT07257055Phase 2Recruiting

Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study

NCT06985472Phase 2Recruiting

Orelabrutinib Combined With Zuberitamab in the Initial Treatment of MZL

Showing all 3 trials

Research Network

Common Treatments

  • Epcoritamab1
  • Acalabrutinib1
  • Zo1
  • Glofitamab1
  • Rituximab1

Active Sponsors

  • M.D. Anderson Cancer Center1
  • Li Zhiming1
  • University of California, Irvine1
  • Genmab1

Top Investigators

Related Conditions

  • Cll1
  • Chronic Lymphocytic Leukemia Cll1
  • Cd201
  • Cll Chronic Lymphocytic Leukemia1
  • Glofitamab1

Activity Timeline